Hopefully not a discount to the market price. T

Quote:

---

The Group has also entered into a Letter of Intent to acquire
a stake in an Over-The-Counter-listed biomedical company,
Amarantus BioScience Holdings, Inc. (“AMBS”) in exchange
for stakes in up to four biotechnology platforms, which it has
identified as part of its collaboration with GRDGS (the “Asset
Swap”). The Asset Swap will give SeD BioMedical Inc. a
major stake in AMBS at a significant discount

---